7 Myths About Prostate Cancer Debunked
Despite how common prostate cancer is in American men, misconceptions about its symptoms, detection, treatment, and management persist.
Prostatectomy
Same-Day Robotic Urologic Surgery During the COVID-19 Crisis Not Riskier
A single-institution study found no significant increase in the risk for complications or readmissions between patients who underwent robotic urologic surgery before and during the COVID-19 pandemic.
Salvage Therapies for Radiorecurrent Prostate Cancer Offer Similar RFS
Surgical and nonsurgical local salvage treatments for prostate cancer (PCa) that recurs following radiation therapy offer similar 5-year recurrence-free survival (RFS) rates, but re-irradiation appears to result in less toxicity, according to a new meta-analysis. A team led by Amar U. Kishan, MD, of the University of California, Los Angeles, analyzed data from 150 studies…
Study: No Need to Rush Surgery for High-Risk Prostate Cancer
Delaying radical prostatectomy for high-risk clinically localized prostate cancer for up to 6 months does not increase the risk for adverse pathologic outcomes, a study found.
Doubling of Radical Surgery Rates for High-Risk Prostate Cancer Reported
By 2016, radical prostatectomy use nearly equaled radiation therapy use for high-risk prostate cancer.
Prostate Cancer Surgery Delay Not Linked to Worse Oncologic Outcomes
Deferring radical prostatectomy for intermediate- and high-risk prostate cancer for several months does not increase the risk for adverse oncologic findings.
Prostate Cancer Therapy Options Have Similar Cost-Effectiveness, Study Finds
Given that the findings do not show major differences between care options in prostate cancer, cost probably shouldn’t be a major factor driving decision making.
Routine Use of Neoadjuvant Docetaxel Plus ADT Not Supported in Localized, High-Risk Prostate Cancer
Patients with localized prostate cancer characterized by high-risk features are at increased risk of a negative outcome following radical prostatectomy.
Radium-223 Plus Sipuleucel-T Found to Slow mCRPC Progression
Combining sipuleucel-T and radium-223 improves progression-free survival among men with metastatic castration-resistant prostate cancer (mCRPC) who have bone predominant metastases, a randomized phase 2 study found.
Prostate Cancer Treatment Side Effects Worse With Prostatectomy
In a study, localized prostate cancer patients reported clinically meaningful differences in urinary, bowel, sexual, and hormonal function by management option up to 5 years of follow-up.
-
Loading...
-
Loading...
Next post in Prostate Cancer
